BVS - Bioventus Inc. Stock Price, Fair Value and News

6.67USD+0.04 (+0.60%)Delayed as of 17 May 2024, 10:53 am ET

Market Summary

USD6.67+0.04

Delayedas of 17 May 2024, 10:53 am

0.60%

BVS Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

BVS Stock Price

View Fullscreen

BVS RSI Chart

BVS Valuation

Market Cap

420.2M

Price/Earnings (Trailing)

-18.22

Price/Sales (Trailing)

0.8

EV/EBITDA

-42.75

Price/Free Cashflow

152.47

BVS Price/Sales (Trailing)

BVS Profitability

EBT Margin

-4.98%

Return on Equity

-10.61%

Return on Assets

-2.9%

Free Cashflow Yield

0.66%

BVS Fundamentals

BVS Revenue

Revenue (TTM)

522.7M

Rev. Growth (Yr)

8.73%

Rev. Growth (Qtr)

-4.41%

BVS Earnings

Earnings (TTM)

-23.1M

Earnings Growth (Yr)

95.7%

Earnings Growth (Qtr)

1.87%

Breaking Down BVS Revenue

52 Week Range

1.476.73

(Low)(High)

Last 7 days

21.3%

Last 30 days

42.7%

Last 90 days

46.1%

Trailing 12 Months

405.3%

How does BVS drawdown profile look like?

BVS Financial Health

Current Ratio

1.53

Debt/Equity

1.63

Debt/Cashflow

0.02

BVS Investor Care

Shares Dilution (1Y)

2.02%

Diluted EPS (TTM)

-0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	522.7M	0	0	0
2023	513.9M	510.6M	502.8M	512.3M
2022	466.4M	496.9M	516.7M	512.1M
2021	324.3M	376.1M	399.1M	430.9M
2020	335.4M	330.7M	325.9M	321.2M
2019	0	0	0	340.1M
2018	0	0	0	319.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bioventus Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	singleton mark leonard	sold	-19,000	4.75	-4,000	svp & cfo
Apr 11, 2024	d'adamio anthony	sold	-14,506	4.75	-3,054	svp & general counsel
Apr 11, 2024	church katrina j	sold	-6,293	4.75	-1,325	svp & chief compliance officer
Apr 10, 2024	church katrina j	acquired	-	-	4,300	svp & chief compliance officer
Apr 10, 2024	singleton mark leonard	acquired	-	-	13,000	svp & cfo
Apr 10, 2024	d'adamio anthony	acquired	-	-	9,925	svp & general counsel
Mar 22, 2024	singleton mark leonard	sold	-29,852	5.3876	-5,541	svp & cfo
Mar 21, 2024	singleton mark leonard	acquired	-	-	18,625	svp & cfo
Mar 15, 2024	church katrina j	sold	-6,644	5.46	-1,217	svp & chief compliance officer
Mar 15, 2024	d'adamio anthony	sold	-17,062	5.46	-3,125	svp & general counsel

Which funds bought or sold BVS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Nantahala Capital Management, LLC	reduced	-51.43	-32,811,300	30,191,300	1.73%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	523	933,297	1,114,510	-%
May 15, 2024	Royal Bank of Canada	reduced	-95.49	-21,000	1,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-13.74	-285,466	1,631,780	0.03%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	24.39	101,807	549,536	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	133	1,616,050	2,857,050	-%
May 15, 2024	Laurion Capital Management LP	unchanged	-	-8,281	615,113	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-297,170	-	-%
May 15, 2024	MARSHALL WACE, LLP	added	26.13	245,683	1,250,330	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	56,878	56,878	-%

Are Funds Buying or Selling BVS?

Are funds buying BVS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BVS

No. of Funds

Unveiling Bioventus Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	9.5%	5,977,471	SC 13G/A
Feb 06, 2024	amp-cf holdings, llc	5.17%	3,255,332	SC 13G/A
Jan 22, 2024	ew healthcare partners acquisition fund, l.p.	19.2%	12,096,702	SC 13G/A
Jun 16, 2023	juniper investment company, llc	7.4%	4,624,431	SC 13D/A
May 24, 2023	juniper investment company, llc	7.4%	4,624,431	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	5.1%	3,168,574	SC 13G
Feb 07, 2023	amp-cf holdings, llc	5.25%	3,255,332	SC 13G/A
Nov 15, 2022	juniper investment company, llc	5.4%	3,347,758	SC 13D/A
Jul 21, 2022	juniper investment company, llc	3.3%	2,051,172	SC 13D
Feb 11, 2022	amp-cf holdings, llc	5.47%	3,255,332	SC 13G

Recent SEC filings of Bioventus Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Bioventus Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

Bioventus Inc. News

Latest updates

Bioventus Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	-4.4%	129,457	135,423	120,794	137,069	119,059	125,834	128,662	140,331	117,290	130,414	108,890	109,816	81,778	98,591	85,908	58,017	78,645	-	-
Gross Profit	2.4%	88,380	86,301	78,850	89,123	73,919	74,189	84,535	96,654	75,702	87,768	79,069	76,313	59,556	73,470	62,464	40,349	57,236	-	-
S&GA Expenses	0.1%	78,406	78,357	69,820	74,844	80,858	77,435	78,955	89,620	86,124	80,881	69,636	69,050	34,686	61,974	50,295	40,533	40,276	-	-
R&D Expenses	-20.4%	2,597	3,262	3,015	3,398	3,771	5,946	4,614	6,366	6,928	7,103	6,153	4,836	947	2,891	3,569	2,596	2,146	-	-
EBITDA Margin	84.7%	-0.03*	-0.22*	-0.27*	-0.51*	-0.51*	-0.35*	-0.29*	-0.04*	-0.05*	0.04*	0.06*	0.09*	0.12*	0.07*	0.05*	0.05*	0.05*	0.05*	0.05*
Income Taxes	220.9%	907	-750	600	381	-146	-10,963	-29,523	1,244	-5,132	-2,725	-882	1,714	-73.00	890	373	-110	39.00	-	-
Earnings Before Taxes	39.6%	-5,075	-8,406	-8,191	-4,350	-100,164	-32,440	-130,558	-6,490	-19,537	-2,750	-3,151	-9,066	24,455	3,141	8,338	-6,090	10,525	-	-
EBT Margin	78.9%	-0.05*	-0.24*	-0.29*	-0.52*	-0.52*	-0.37*	-0.31*	-0.06*	-0.07*	0.02*	0.04*	0.07*	0.09*	0.05*	0.03*	0.03*	0.03*	0.03*	0.02*
Net Income	1.9%	-5,982	-6,096	-7,303	-3,681	-139,150	-31,930	-108,245	-7,252	-11,277	-364	-1,071	-4,126	-1,041	2,776	8,457	-5,766	10,944	-	-
Net Income Margin	85.5%	-0.04*	-0.30*	-0.36*	-0.55*	-0.56*	-0.31*	-0.25*	-0.04*	-0.04*	-0.02*	0.04*	0.04*	0.05*	0.05*	0.02*	0.02*	0.02*	0.02*	-0.04*
Free Cashflow	-162.9%	-6,296	10,005	-10,351	9,398	-1,070	1,841	-2,350	909	-23,979	4,165	8,661	16,057	-19,412	11,199	19,560	7,069	17,392	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-2.1%	794	811	811	837	887	1,373	1,398	1,209	1,197	1,226	655	647	643	494	472
Current Assets	-0.8%	266	268	249	261	309	273	271	277	245	263	246	290	271	212	183
Cash Equivalents	-31.9%	25.00	37.00	27.00	29.00	47.00	30.00	34.00	41.00	83.00	99.00	131	138	129	87.00	65.00
Inventory	6.2%	97.00	91.00	98.00	96.00	88.00	85.00	77.00	69.00	65.00	62.00	37.00	34.00	40.00	29.00	27.00
Net PPE	-	-	-	-	-	-	-	-	-	25.00	23.00	10.00	9.00	8.00	7.00	4.00
Goodwill	0%	7.00	7.00	7.00	7.00	7.00	7.00	15.00	60.00	148	148	53.00	52.00	3.00	50.00	50.00
Liabilities	-2.2%	577	590	585	604	647	960	1,019	689	675	618	424	427	423	350	327
Current Liabilities	-1.2%	173	175	161	179	196	304	288	199	172	181	161	158	149	123	89.00
Long Term Debt	-3.2%	355	367	375	375	404	385	393	351	348	340	162	166	170	173	188
LT Debt, Current	28.6%	36.00	28.00	20.00	11.00	41.00	33.00	31.00	23.00	20.00	18.00	15.00	15.00	15.00	15.00	10.00
LT Debt, Non Current	-100.0%	-	367	375	375	404	385	393	351	348	340	162	166	170	173	188
Shareholder's Equity	25.3%	217	174	178	233	240	325	451	592	594	608	230	219	220	144	143
Retained Earnings	-1.4%	-326	-321	-315	-308	-304	-165	-133	-25.13	-17.88	-6.60	-6.24	-5.17	-1.04	-144	-141
Additional Paid-In Capital	0.6%	497	494	492	491	492	491	478	474	468	473	158	146	143	-	-
Shares Outstanding	1.2%	63.00	63.00	63.00	62.00	62.00	61.00	61.00	61.00	60.00	45.00	42.00	42.00	42.00	-	-
Minority Interest	-2.9%	46.00	48.00	49.00	50.00	52.00	87.00	36.00	72.00	72.00	141	78.00	78.00	78.00	2.00	3.00
Float	-	-	-	-	75.00	-	-	-	206	-	-	-	263	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Cashflow From Operations	-157.9%	-6,005	10,374	-8,315	10,795	2,490	5,244	-701	2,939	-21,019	13,117	10,587	17,329	-18,042	25,447	20,841	7,820	17,691	-	-
Share Based Compensation	46.0%	2,591	1,775	1,833	-2,732	1,846	3,432	4,648	4,616	4,889	6,109	5,938	5,853	1,944	-	-	-	-	-	-
Cashflow From Investing	-69.2%	-1,000	-591	-2,036	33,500	-15,066	-3,403	-56,334	-52,025	-4,674	-221,278	-13,186	-2,648	-46,648	-1,711	-17,759	-579	-451	-	-
Cashflow From Financing	-30200.0%	-4,242	-14.00	8,229	-62,248	27,380	-5,438	50,654	7,655	9,205	176,308	-4,346	-6,117	107,526	-9,878	-57,116	-11,357	48,782	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BVS Income Statement

2024-03-30

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Income Statement [Abstract]
Net sales	$ 129,457	$ 119,059
Cost of sales (including depreciation and amortization of $10,025 and $14,339, respectively)	41,077	45,140
Gross profit	88,380	73,919
Selling, general and administrative expense	78,406	80,858
Research and development expense	2,597	3,771
Restructuring costs	0	317
Change in fair value of contingent consideration	295	287
Depreciation and amortization	1,755	2,129
Impairments of assets	0	78,615
Operating income (loss)	5,327	(92,058)
Interest expense, net	10,339	9,694
Other expense (income)	63	(1,588)
Other expense	10,402	8,106
Loss before income taxes	(5,075)	(100,164)
Income tax expense (benefit), net	907	(146)
Net loss from continuing operations	(5,982)	(100,018)
Loss from discontinued operations, net of tax	0	(74,429)
Net loss	(5,982)	(174,447)
Loss attributable to noncontrolling interest - continuing operations	1,412	20,360
Loss attributable to noncontrolling interest - discontinued operations	0	14,937
Net loss attributable to Bioventus Inc.	(4,570)	(139,150)
Change in foreign currency translation adjustments	(585)	657
Comprehensive loss	(6,567)	(173,790)
Comprehensive loss attributable to noncontrolling interest - continuing operations	1,528	20,226
Comprehensive loss attributable to noncontrolling interest - discontinued operations	0	14,937
Comprehensive loss attributable to Bioventus Inc.	$ (5,039)	$ (138,627)
Loss per share of Class A common stock
Loss per share of Class A common stock from continuing operations, basic (in dollars per share)	$ (0.07)	$ (1.28)
Loss per share of Class A common stock from continuing operations, diluted (in dollars per share)	(0.07)	(1.28)
Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)	0	(0.96)
Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)	0	(0.96)
Loss per share of class A common stock, basic (in dollars per share)	(0.07)	(2.24)
Loss per share of class A common stock, diluted (in dollars per share)	$ (0.07)	$ (2.24)
Weighted-average shares of Class A common stock outstanding
Basic (in shares)	63,380,187	62,124,752
Diluted (in shares)	63,380,187	62,124,752

BVS Balance Sheet

2024-03-30

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,173	$ 36,964
Accounts receivable, net	125,541	122,789
Inventory	97,005	91,333
Prepaid and other current assets	18,184	16,913
Total current assets	265,903	267,999
Property and equipment, net	34,532	36,605
Goodwill	7,462	7,462
Intangible assets, net	470,668	482,350
Operating lease assets	12,462	13,353
Investment and other assets	3,211	3,141
Total assets	794,238	810,910
Current liabilities:
Accounts payable	19,099	23,038
Accrued liabilities	113,605	119,795
Current portion of long-term debt	35,811	27,848
Other current liabilities	4,806	4,816
Total current liabilities	173,321	175,497
Long-term debt, less current portion	355,430	366,998
Deferred income taxes	1,294	1,213
Contingent consideration	18,445	18,150
Other long-term liabilities	28,316	27,934
Total liabilities	576,806	589,792
Commitments and contingencies (Note 11)
Stockholders’ Equity
Additional paid-in capital	496,977	494,254
Accumulated deficit	(326,106)	(321,536)
Accumulated other comprehensive income	325	794
Total stockholders’ equity attributable to Bioventus Inc.	171,276	173,591
Noncontrolling interest	46,156	47,527
Total stockholders’ equity	217,432	221,118
Total liabilities and stockholders’ equity	794,238	810,910
Common Class A
Stockholders’ Equity
Common stock, value	64	63
Common Class B
Stockholders’ Equity
Common stock, value	$ 16	$ 16

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

CEO	Mr. Anthony P. Bihl III
WEBSITE	bioventus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	950

Bioventus Inc. Frequently Asked Questions

What is the ticker symbol for Bioventus Inc.? What does BVS stand for in stocks?

BVS is the stock ticker symbol of Bioventus Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bioventus Inc. (BVS)?

As of Thu May 16 2024, market cap of Bioventus Inc. is 420.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BVS stock?

You can check BVS's fair value in chart for subscribers.

What is the fair value of BVS stock?

You can check BVS's fair value in chart for subscribers. The fair value of Bioventus Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bioventus Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bioventus Inc. a good stock to buy?

The fair value guage provides a quick view whether BVS is over valued or under valued. Whether Bioventus Inc. is cheap or expensive depends on the assumptions which impact Bioventus Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BVS.

What is Bioventus Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, BVS's PE ratio (Price to Earnings) is -18.22 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BVS PE ratio will change depending on the future growth rate expectations of investors.